Dual-targeted Mcl-1 siRNA-liposome nanoparticles for targeted therapy of allergic rhinitis via CD4+CD44+ T cell modulation

Read full text Summarise with VIRAT
Authors: Jinbiao Xie, Lihua Mo, Jianwen Zhong, Jinna Yang, Shuyao Qiu, Yanyu Ye, Ping–Chang Yang, Xiangqian Luo, Dabo Liu
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To construct anti-CD4/anti-CD44 dual-modified Mcl-1 siRNA-loaded liposome nanoparticles (LPN) targeting allergic rhinitis (AR)-related CD4 + CD44 + T cells, and verify its in vitro Mcl-1 silencing and anti-inflammatory effects, in vivo therapeutic efficacy on ovalbumin (OVA)-induced mouse AR, as well as the underlying mechanism. The physicochemical and AR-related CD4 + CD44 + T cell targeting properties of dual-targeted LPN were systematically characterized. Its in vitro silencing efficiency on Mcl-1 and regulatory effect on Th2 polarization were detected in primary AR-related CD4 + CD44 + T cells. After nasal instillation of LPN in OVA-induced AR mice, therapeutic efficacy was evaluated by behavioral, histopathological and humoral indicators; the mechanism was explored by detecting Mcl-1 expression, inflammatory cell apoptosis and CD4 + IL-4 + CD44 + Th2 cell infiltration in nasal mucosa. The dual-targeted LPN had favorable physicochemical properties (138.6±12.3 nm, +21.5±3.1 mV), a high siRNA encapsulation efficiency (89.2±4.5%), 76.8% cumulative siRNA release at 48 h, and significantly higher targeting affinity than single/non-targeted LPN (P

Fields of Study & Subjects

RNA Interference and Gene Delivery Allergic Rhinitis and Sensitization Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Allergy medicine.
Volume
8
Pages
100109–100109
Publication date
26 March 2026
Language
EN